Physician profile
Bernard Borbely
NPI 1063410991
$555.37
in general payments reported to CMS, 2019-2025
10 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2021: $33.57 · 2022: $31.29 · 2023: $15.66 · 2024: $14.58 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $150 · Education: $135 · Food and Beverage: $99.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $150.00 |
| Education | $134.75 |
| Food and Beverage | $99.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $265.65 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $66.91 | 2019-2022 | |
| Pulmonx Corporation | $48.37 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Harmony Biosciences LLC | $35.45 | 2024-2025 | |
| Insmed, INC. | $34.76 | 2025 | Brinsupri |
| Vapotherm INC | $33.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.92 | 2019 | |
| Mylan Specialty L.P. | $13.97 | 2019 | |
| Glaxosmithkline, LLC. | $13.79 | 2019 | |
| Csl Behring | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Borbely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.